TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26018817

Group type: EXPERIMENTAL
Intervention: Nursing interventions based on the Health Belief Model and the Health Promotion Model
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 25438937

Group type: EXPERIMENTAL
Intervention: High dose oral vitamin D3 (6000 IU daily for 6 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22560018

Group type: EXPERIMENTAL
Intervention: Beta-blocker (BB) dose
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: Higher doses of BB
Number of subjects: 2331
Study: 19346625

Group type: EXPERIMENTAL
Intervention: Elastic resistance exercise program for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 17470957

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (40 sessions)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 85
Study: 15182896

Group type: EXPERIMENTAL
Intervention: Network therapy (NT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Medication management (MM)
Number of subjects: 66
Study: 12394686

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 4863

Group type: COMPARATOR
Intervention: Control (resection alone or resection plus another treatment)
Number of subjects: 4863

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG) with maintenance treatment
Number of subjects: 4863
Study: 9813759

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study: 8132849

Group type: EXPERIMENTAL
Intervention: Naproxen tablets (250 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Naproxen suspension (250 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Naproxen tablets and suspension
Number of subjects: 23
Study: 2628331

Group type: EXPERIMENTAL
Intervention: Staples
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 100
Study: 788749

Group type: COMPARATOR
Intervention: Conventional oxprenolol (80 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (160 mg)
Number of subjects: 6
Study: 31881340

Group type: EXPERIMENTAL
Intervention: Intraoperative lumbar drainage (LD)
Number of subjects: 189
Study: 30429032

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 (cohort A)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 plus bevacizumab 15 mg/kg (cohort B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m2 (cohort C)
Number of subjects: 74
Study: 27440535

Group type: EXPERIMENTAL
Intervention: Conventional grape juice (400 mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Organic grape juice (400 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 24
Study: 24432999

Group type: EXPERIMENTAL
Intervention: 100 mg/d sitagliptin with insulin therapy (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin therapy without sitagliptin (group B)
Number of subjects: 30
Study: 22918176

Group type: EXPERIMENTAL
Intervention: Rank‐Ordered Calories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colored Calories
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calories
Number of subjects: 0

Group type: COMPARATOR
Intervention: No Calories
Number of subjects: 0
Study: 20934756

Group type: EXPERIMENTAL
Intervention: Microdebrider tonsillotomy (MIT)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Electrocautery tonsillectomy (ECT)
Number of subjects: 501
Study: 18661005

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 7 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Analgesic alone
Number of subjects: 120
Study: 15955034

Group type: EXPERIMENTAL
Intervention: Recent-onset TM (</=1 year)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Long-duration TM (>1 year)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: TM with medication overuse (recent onset)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: TM without medication overuse (recent onset)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recent onset of chronic daily headache (CDH)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Recent onset of migraine (<36 months)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Younger ages (</=15 years)
Number of subjects: 117
Study: 12892193

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 112

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 112

Group type: COMPARATOR
Intervention: Radiation therapy (XRT)
Number of subjects: 112
Study: 10879896

Group type: EXPERIMENTAL
Intervention: Intervention including computerized or manual cancer screening reminders, continuing medical education seminars, Vietnamese-language health education materials, newsletters, and oncology data-query programs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract)
Number of subjects: 20
Study: 8970830

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 12
Study: 1279290

Group type: EXPERIMENTAL
Intervention: Doxazosin (1-16 mg) once daily for 16 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 15
Study: 3905414

Group type: COMPARATOR
Intervention: BTS 49 465 (200 mg oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 31060545

Group type: EXPERIMENTAL
Intervention: Integrated chronic disease clinic care for hypertension
Number of subjects: 4554

Group type: EXPERIMENTAL
Intervention: Visit frequency determined by drug supply chain rather than clinical indication
Number of subjects: 4554
Study: 29622029

Group type: EXPERIMENTAL
Intervention: GP model of hospital-at-home care
Number of subjects: 131

Group type: COMPARATOR
Intervention: Hospital specialist model of hospital-at-home care
Number of subjects: 131
Study: 26662208

Group type: EXPERIMENTAL
Intervention: Standard dose rituximab (375 mg/m² weekly)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low dose rituximab (20 mg/m² 3x week)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combination mAb therapy (alemtuzumab with either standard or low dose rituximab)
Number of subjects: 31
Study: 23899405

Group type: EXPERIMENTAL
Intervention: MYLO
Number of subjects: 48

Group type: COMPARATOR
Intervention: ELIZA
Number of subjects: 48
Study: 22400810

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT) 1 gram/20 mg daily, increased to 2 tablets daily after 4 weeks
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796
Study: 20170751

Group type: EXPERIMENTAL
Intervention: 10 weekly 1-hour sessions of CBT
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: four 1-hour CBT sessions over 10 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: wait list control
Number of subjects: 71
Study: 18594925

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted total gastrectomy (LATG)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional open total gastrectomy (OTG)
Number of subjects: 38
Study: 16002819

Group type: EXPERIMENTAL
Intervention: High-saturated fatty acid (SFA) diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-fat and high-carbohydrate diet (CHO diet)
Number of subjects: 59

Group type: COMPARATOR
Intervention: High-monounsaturated fatty acid (MUFA) diet (Mediterranean diet)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SFA diet
Number of subjects: 59
Study: 12486652

Group type: EXPERIMENTAL
Intervention: Centrifugal pump for cardiopulmonary bypass (n = 54)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Roller pump for cardiopulmonary bypass (n = 49)
Number of subjects: 103
Study: 10509772

Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (benign gastrointestinal diseases)
Number of subjects: 18
Study: 8610948

Group type: EXPERIMENTAL
Intervention: trimethoprim‐sulfamethoxazole
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: clindamycin‐primaquine
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: dapsone‐trimethoprim
Number of subjects: 181

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 181
Study: 1750635

Group type: EXPERIMENTAL
Intervention: Interpleural infusion of bupivacaine (Group B, n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous infusion of pethidine (Group P, n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interpleural infusion of bupivacaine (Group B)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous infusion of pethidine (Group P)
Number of subjects: 26
Study: 7199923

Group type: EXPERIMENTAL
Intervention: Ro 12-2503
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30194380

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg per day for 1 week, then 50 mg per day up to 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 0
Study: 27761987

Group type: EXPERIMENTAL
Intervention: Vigorous/Moderate exercise
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 220
Study: 25591756

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) at a dose of 10 μmol/L in OGD+MDZ group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) at a dose of 10 μmol/L and IL‐6 at a dose of 50 ng/mL in OGD+MDZ+IL‐6 group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen glucose deprivation (OGD) group
Number of subjects: 0
Study: 24307262

Group type: EXPERIMENTAL
Intervention: Na(18)F PET/CT imaging at 45, 90, and 180 minutes after Na(18)F administration
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Delayed Na(18)F PET/CT imaging
Number of subjects: 38
Study: 22566743

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (TPAD‐IC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard medical therapy (CPAD‐IC)
Number of subjects: 16
Study: 19164456

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine (docetaxel 60 mg/m² on day 1 and day 8, gemcitabine 800 mg/m² on days 1 and 8, every 21 days)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Docetaxel alone (docetaxel 60 mg/m² on day 1)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 130
Study: 17444309

Group type: EXPERIMENTAL
Intervention: BIS monitoring (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sedation management (n=25)
Number of subjects: 50
Study: 15871587

Group type: EXPERIMENTAL
Intervention: Sternocleidomastoid muscle flap reconstruction
Number of subjects: 24

Group type: COMPARATOR
Intervention: No flap reconstruction (Control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 12450060

Group type: EXPERIMENTAL
Intervention: Etidronate (intermittent cyclical)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Strength training (3 d/week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (non-exercising controls)
Number of subjects: 48
Study: 9522199

Group type: EXPERIMENTAL
Intervention: Combined intervention (telephone and first interview)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Telephone‐alone intervention
Number of subjects: 109

Group type: COMPARATOR
Intervention: Usual intake procedure
Number of subjects: 109
Study: 10577572

Group type: EXPERIMENTAL
Intervention: Candoxatril 400 mg/day
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Frusemide 40 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 1802923

Group type: EXPERIMENTAL
Intervention: Orbital radiotherapy combined with systemic glucocorticoids (Group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orbital radiotherapy alone (Group 2)
Number of subjects: 30
Study: 6402051

Group type: EXPERIMENTAL
Intervention: 3.5% amino acid infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% dextrose (D5W) infusion
Number of subjects: 20
Study: 30985391

Group type: EXPERIMENTAL
Intervention: Early goal-directed therapy
Number of subjects: 1591

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1591
Study: 29218707

Group type: EXPERIMENTAL
Intervention: Rosuvastatin administered with food
Number of subjects: 179

Group type: COMPARATOR
Intervention: Rosuvastatin administered in a fasting state
Number of subjects: 179
Study: 26765479

Group type: COMPARATOR
Intervention: Conventional dosing regimen (group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic model-based dosing scheme (group B)
Number of subjects: 70
Study: 23392267

Group type: EXPERIMENTAL
Intervention: New treatment model (intervention group)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard protocol (treatment-as-usual control group)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 184
Study: 22337471

Group type: EXPERIMENTAL
Intervention: GRT9906 (120-240 mg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Tramadol (200-400 mg)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: GRT9906
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: GRT9906 and Tramadol
Number of subjects: 117
Study: 19682845

Group type: EXPERIMENTAL
Intervention: 3.5% polygeline
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch
Number of subjects: 30
Study: 17947505

Group type: EXPERIMENTAL
Intervention: 40 min/day of treadmill exercise while supine in 53 mmHg LBNP, followed by 5 min of resting LBNP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 15984517

Group type: EXPERIMENTAL
Intervention: WHF arm (study group), 1000 mg/m2 of 5-FU administered over the course of 5 hr once a week by hepatic arterial infusion
Number of subjects: 91

Group type: COMPARATOR
Intervention: CVI arm (control group), 300 mg/m2 of 5-FU administered as a continuous intravenous infusion daily for 5 days followed by 2 days' rest
Number of subjects: 91
Study: 12018753

Group type: EXPERIMENTAL
Intervention: School-based and family-based intervention
Number of subjects: 4776

Group type: EXPERIMENTAL
Intervention: School-based intervention only
Number of subjects: 4776

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4776
Study: 9256127

Group type: EXPERIMENTAL
Intervention: Alternating schedule of chemotherapy and irradiation (CDE chemotherapy split into four courses of five daily fractions delivered on days 14 to 21 of the second and subsequent chemotherapy courses)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Sequential schedule of chemotherapy and irradiation (five courses of CDE chemotherapy followed by thoracic irradiation 50 Gy in 20 daily fractions)
Number of subjects: 335
Study: 8289038

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U given intravenously) at home
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: All patients (both treatment groups)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Patients who died
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Survivors with infarction
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Survivors without infarction
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Patients with infarction with Q-waves
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Patients with infarction without Q-waves
Number of subjects: 311

Group type: COMPARATOR
Intervention: Thrombolytic treatment at home
Number of subjects: 311
Study: 3560788

Group type: EXPERIMENTAL
Intervention: Alinidine (3 X 40 mg for 2 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol (2 X 40 mg for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30209286

Group type: EXPERIMENTAL
Intervention: Placebo 'analgesic' pills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological traits
Number of subjects: 0
Study: 27616217

Group type: EXPERIMENTAL
Intervention: Family-centered brief intervention (up to five home sessions focusing on physical activity and healthy eating)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Family-centered brief intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care control (CVD risk assessment and one-time consultation)
Number of subjects: 320
Study: 23906510

Group type: EXPERIMENTAL
Intervention: Delayed match‐to‐sample secondary task involving photographs of positive emotional valence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed match‐to‐sample secondary task involving photographs of negative emotional valence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed match‐to‐sample secondary task involving photographs of neutral emotional valence
Number of subjects: 0

Group type: COMPARATOR
Intervention: No secondary task
Number of subjects: 0
Study: 22716928

Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar (80 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar (592 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test cookie (80 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Test cookie (592 kcal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soybean nutrition bar and Test cookie
Number of subjects: 0
Study: 21330816

Group type: EXPERIMENTAL
Intervention: CD group (trained on the patient simulator performing general anesthesia for emergency CD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: SHAM group (trained on the simulator using a different general anesthetic scenario unrelated to obstetric anesthesia)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 19074082

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic platelet transfusions
Number of subjects: 0
Study: 16422806

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 12875474

Group type: EXPERIMENTAL
Intervention: Supervised physical exercise (PE) program supervised by a physiotherapist
Number of subjects: 18

Group type: COMPARATOR
Intervention: Recommended exercise (oral and written instructions)
Number of subjects: 18
Study: 10375185

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuploride and chlormadinone acetate) for 3 months preoperatively followed by radical prostatectomy and adjuvant endocrine therapy (leuploride only)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Radical prostatectomy followed by 3 months of androgen deprivation and subsequent adjuvant endocrine therapy
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Preoperative androgen deprivation for stage C cancer patients
Number of subjects: 176
Study: 9038462

Group type: EXPERIMENTAL
Intervention: Group A: 1 ml.kg‐1 of 0.25% bupivacaine with 0.25 mg.kg‐1 of preservative‐free ketamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group B: 1 ml.kg‐1 of 0.25% bupivacaine with 0.5 mg.kg‐1 of ketamine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group C: 1 ml.kg‐1 of 0.25% bupivacaine with 1 mg.kg‐1 of ketamine
Number of subjects: 60
Study: 1442655

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg Ca as carbonate daily with meals)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no calcium supplementation)
Number of subjects: 109
Study: 3900116

Group type: EXPERIMENTAL
Intervention: Ritalin 0.3 mg/kg bid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ritalin 0.7 mg/kg bid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31842841

Group type: EXPERIMENTAL
Intervention: Succinylcholine (group SC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rocuronium-sugammadex (group RS)
Number of subjects: 42
Study: 30208380

Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 221

Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 221
Study: 27129472

Group type: EXPERIMENTAL
Intervention: Yoga intervention (standardized weekly group yoga class with home practice)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Education intervention (self-care book)
Number of subjects: 120
Study: 25371053

Group type: EXPERIMENTAL
Intervention: anti-TNF (adalimumab, Humira®, Abbott) 40 mg s.c.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: oral methylprednisolone 20 mg/day during 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: control
Number of subjects: 30
Study: 22951084

Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum tolerable daily dose of 1800 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 19486025

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 400 IU twice daily (D group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vitamin D(3) oil 97333 IU every 4 months (4 M group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 17998780

Group type: EXPERIMENTAL
Intervention: Platelet-leukocyte gel (PLG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PLG)
Number of subjects: 40
Study: 16185403

Group type: EXPERIMENTAL
Intervention: Intravenous injection of L-arginine (2% of total caloric value)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Compound 14 amino acid injection (2% of total caloric value)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 10